We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIL icon
51
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.9B
$2M 0.33%
21,786
-10,714
-33% -$982K
ALEC icon
52
Alector
ALEC
$203M
$2M 0.33%
428,802
+233,491
+120% +$1.25M
TEVA icon
53
Teva Pharmaceuticals
TEVA
$40.6B
$1.95M 0.32%
108,171
+5,050
+5% +$88.4K
KALA icon
54
KALA BIO
KALA
$14.2M
$1.74M 0.28%
6,121
– –
KRRO icon
55
Korro Bio
KRRO
$175M
$1.65M 0.27%
49,451
+42,241
+586% +$1.78M
ALDX icon
56
Aldeyra Therapeutics
ALDX
$95.9M
$1.63M 0.26%
+302,212
New +$1.44M
TIL icon
57
Instil Bio
TIL
$49.4M
$1.6M 0.26%
+23,707
New +$558K
KDK
58
Kodiak AI
KDK
$842M
$1.51M 0.24%
+138,966
New +$1.49M
MCK icon
59
CALL
McKesson
MCK
$102B
$1.48M 0.24%
+3,000
New +$1.67M
NVO
60
CALL
Novo Nordisk
NVO
$203B
$1.19M 0.19%
+10,000
New +$1.33M
BNTX icon
61
BioNTech
BNTX
$22.9B
$1.19M 0.19%
+10,000
New +$919K
MLTX icon
62
MoonLake Immunotherapeutics
MLTX
$1.53B
$1.18M 0.19%
23,457
+18,657
+389% +$874K
NVNO
63
enVVeno Medical
NVNO
$6.78M
$1.17M 0.19%
9,950
+4,186
+73% +$769K
PCVX icon
64
Vaxcyte
PCVX
$8.5B
$1.15M 0.19%
10,097
-2,153
-18% -$194K
IRON icon
65
Disc Medicine
IRON
$2.97B
$1.11M 0.18%
+22,564
New +$1.06M
XENE icon
66
Xenon Pharmaceuticals
XENE
$6.24B
$1.1M 0.18%
27,903
+23,203
+494% +$936K
BEAM icon
67
Beam Therapeutics
BEAM
$2.81B
$1.08M 0.17%
43,900
-28,900
-40% -$747K
NUVL
68
DELISTED
Nuvalent
NUVL
$1.07M 0.17%
+10,442
New +$866K
CTMX icon
69
CytomX Therapeutics
CTMX
$734M
$1.07M 0.17%
903,959
+331,789
+58% +$421K
AVDL
70
DELISTED
Avadel Pharmaceuticals
AVDL
$1.06M 0.17%
+80,900
New +$1.23M
IBIO icon
71
iBio
IBIO
$69.1M
$1.06M 0.17%
476,212
-93,788
-16% -$185K
PFE icon
72
Pfizer
PFE
$149B
$1.04M 0.17%
35,950
-4,000
-10% -$117K
EXAS
73
DELISTED
Exact Sciences
EXAS
$1.04M 0.17%
15,200
+14,600
+2,433% +$824K
KZR
74
DELISTED
Kezar Life Sciences
KZR
$1.03M 0.17%
133,827
+25,177
+23% +$152K
BCAX
75
Bicara Therapeutics
BCAX
$1.81B
$1.03M 0.17%
+40,440
New +$1.03M
1 2
3
4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.